CLL MRD Flow Panel | NeoGenomics Laboratories

Code

FLG-CLMR-03BX

Panel

Active-Compendium

88184(x1), 88185(x7). Add 88187(x1) for global.

Clinical

Oncology,Pathology

Bone marrow aspirate: 2-3 mL EDTA preferred. Sodium heparin is acceptable.
Peripheral blood: 5-6 mL EDTA preferred. Sodium heparin is acceptable.
NY Clients: Please provide Date and Time of Collection.
Note: Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.

Hematologic Diseases

Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)

Mon, 01/13/2025 - 12:00

Wed, 01/22/2025 - 12:00

Flow Cytometry

Global

Flag Active

True

Orderable Test Description

Available as global test only. Markers are CD3, CD5, CD19, CD20, CD22, CD43, CD79b, CD81 (8 markers).

Orderable Turn Around Time

1 Day

Keywords

ERIC

residual disease

Meta Description

Available as global test only. Markers are CD3, CD5, CD19, CD20, CD22, CD43, CD45, CD79b, and CD81 (9 markers). The CLL MRD Flow Panel follows the strategy developed by the European Research Initiative in CLL (ERIC) and can detect minimal residual disease at the 0.01% level.

Extra Note

Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report. NYS clients please provide date and time of Collection.

Orderable Biomarkers

NY Approved

True

Orderable Biomarkers JSON

{"Flow Cytometry": {"Markers": ["CD3", "CD22", "CD58", "CD20", "CD81", "CD43", "CD79b", "CD19"]}}

Keywords string

ERIC, residual disease CLL MRD Flow Panel

Title URL

cll-mrd-flow-panel